Who
Yasunori Kaneko
Director
Company insider
Files Form 4 as: Director, Arcus Biosciences; 10% owner, Collegium Pharmaceutical; 10% owner, Protara Therapeutics; 10% owner, Tetraphase Pharmaceuticals; Director, Renovis.
In numbers
- Trades disclosed
- 58
- Buys
- 5
- Sells
- 1
- Bought
- $8.9M
- Sold
- $560K
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 16 Jan 2006
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —5,700 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,900 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,900 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —5,700 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,300 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 27 Feb 2025filed 27 Feb 2025 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Bought | $201K20,000 at $10.06 | filing |
| 6 Jun 2024filed 7 Jun 2024 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —8,400 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —6,800 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,800 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —4,100 at $0.00 | filing |
| 3 Jun 2021filed 7 Jun 2021 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 3 Jun 2021filed 7 Jun 2021 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,100 at $0.00 | filing |
| 23 Apr 2021filed 26 Apr 2021 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Bought | $130K4,133 at $31.37 | filing |
| 5 Jun 2020filed 8 Jun 2020 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 5 Jun 2020filed 8 Jun 2020 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code M | $280K35,000 at $7.99 | filing |
| 4 Jun 2020filed 8 Jun 2020 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 4 Jun 2020filed 8 Jun 2020 | RCUS Arcus BiosciencesBiotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
News
Invivyd (NASDAQ:IVVD) and Arcus Biosciences (NYSE:RCUS) Critical ContrastRCUS · themarketsdaily.com · 19 Oct 2026Valion Bio, Inc. Common Stock (NASDAQ:VBIO) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head ComparisonRCUS · themarketsdaily.com · 18 Oct 2026Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rated "Moderate Buy" by Sell-Side BrokeragesRCUS · dailypolitical.com · 16 Oct 2026Protara Therapeutics (NASDAQ:TARA) Stock Price Down 5.3% – Here's WhyTARA · themarketsdaily.com · 15 Oct 2026Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Consensus Price Target of $48.71COLL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Yasunori Kaneko; 5 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.